Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Viridian

Best conception supplements to support pregnancy

Are you planning for a baby? Help your chances of getting pregnant with our pick of the best prenatal supplements

Evening Standard

3 Top Small-Cap Tech Picks for Investors This Month

Wall Street believes these three small companies have significant upside potential.

Barchart

Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat

Shares of VRDN stock collapsed Tuesday after Viridian Therapeutics unveiled the results of its chronic treatment for thyroid eye disease.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

EVE Online celebrates 20th anniversary with a fireworks show and a free expansion

Viridian is set to come out in June.

PC Gamer

Viridian Cannabis Credit Rankings Prioritize Liquidity

Over the last two weeks, TerrAscend (OTC: TRSSF), Verano (OTC: VRNOF), and Acreage (OTC: ACRDF) have obtained new credit agreements with interest rates in the low teens, demonstrating tha

Benzinga

Why Viridian's CEO Isn't Sweating His Company's Second-Place Position

Viridian Therapeutics hopes to follow Horizon Therapeutics with a best thyroid eye disease drug, and the IPO stock is on a run.

Investors Business Daily

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets

Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged.

Investors Business Daily

'The World's Largest Database Of Cannabis Deals Gives Us Incredible Market Intelligence And An Edge,' Says Viridian's Scott Greiper

Lowered valuations for cannabis companies are leading to a shift in the way capital is raised and merger and acquisition activity is occurring in the cannabis space. In this context, cannabis investors can leverage their understanding of M&A to anticipate corporate strategic moves and profit.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

64 stories

Investor Business Daily

63 stories

CHPT

46 stories

Medicines and Healthcare products Regulatory Agency

23 stories

Nature Medicine

23 stories

Viridian Cannabis Deal Tracker

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.